Cogent Biosciences Inc COGT

Healthcare Biotechnology

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company also develops CGT4859, a reversible and selective fibroblast growth factor receptor 2 inhibitor in Phase 1 trial for patients with documented FGFR mutations, including advanced cholangiocarcinoma. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. Cogent Biosciences, Inc. is headquartered in Waltham, Massachusetts.

NDAQ:COGT - Post by User

Cogent Biosciences Inc

Bullboard Posts

Next >>

(4)
•••

Post by AviseAnalyticson Nov 12, 2021 7:06am

188 Views

Post# 34118399

5 STOCKS FOR YOUR INVESTMENT WATCHLIST!

CYCN COGT QIPT CHS POLY

https://www.aviseanalytics.com/5-stocks-for-your-investment-watchlist/

Technology Industry has been focused on minimizing the impact of COVID-19 and marching ahead with its innovations and breakthroughs, be it critical security systems, innovative marketing solutions or cutting-edge data analytics and search technology.

We take a look at some tech companies that are impervious to the scare and offer a very attractive upside in the long run.

https://www.aviseanalytics.com/5-stocks-for-your-investment-watchlist/

Bullboard Posts

Next >>

Five key facts you need to know about the Sedna Copper Project